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$38,700 for CRHD. Total annual hospitalization charges
for ARF and CRHD were estimated at $1.9 billion in year
2002 US dollars. CONCLUSIONS: Rheumatic fever 
and its sequelae CRHD represent a signiﬁcant economic
burden in the US. Total annual hospitalization charges
estimated for ARF and CRHD are substantially higher
than the recent estimate by the Institute of Medicine (Vac-
cines for the 21st Century, A Tool for Decisionmaking,
2000) for all group A streptococcus-associated hospital-
izations (<$100 million).
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OBJECTIVES: Our objective is to demonstrate software
technology that predicts the toll of smoking and deter-
mines the return on investment (ROI) of tobacco control
programs in a managed care setting. METHODS: We
developed a software application that incorporates a
Markov model to track changes in smoking status in 
6-month cycles over 20 years. Important features of a
managed care setting such as member turnover and plan
beneﬁt design are incorporated in the model. A curvi-
linear function of quit duration was used to estimate
disease risk for former smokers. The model predicts all
medical costs associated with a given population by esti-
mating costs for 39 conditions, 17 of which are smoking
related. It calculates case rates and cost per case by
smoking status for each condition using epidemiological
concepts of relative risk and smoking-attributable frac-
tion. Additionally, non-medical costs associated with
smoking are estimated from the employer and societal
perspectives. RESULTS: The smoking prevalence in a
commercially insured health plan of 980,292 members is
predicted to increase to 21% in year 2022 from 16% in
2002, if there is no change in smoking behavior. Current
smokers are predicted to contribute 36% of the medical
costs of smoking related conditions at year 2002 and
increase their share to 44% in 2022. Relative to all
medical costs, this is equivalent to 19% in 2002 and 28%
in 2022. The incremental non-medical costs per current
smoker employee are estimated to be $2047 in 2002.
CONCLUSIONS: MediSave Smoking Cessation enables
rapid prediction of the baseline tobacco burden on
medical as well as non-medical costs in a managed care
context, and permits estimation of the ROI of interven-
tion programs. Its user-friendly format facilitates sensi-
tivity analyses of various program characteristics. As
such, it is a useful tool to build the business case for
tobacco control programs.
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OBJECTIVES: Our objective is to estimate the medical
and non-medical savings associated with two smoking
cessation interventions in a Minnesota health plan using
a new predictive technology, and to determine the return
on investment (ROI). METHODS: We developed a
Markov model to simulate the smoking behaviors, health
outcomes and impact of tobacco control programs in a
managed care setting. We integrated the model into a soft-
ware application called MediSave and used it to deter-
mine the combined impact of two interventions, which
include coverage of smoking cessation pharmaceutical
aids (such as buproprion or nicotine substitutes) and
physician advice. Program participation and cost data
were provided by the health plan. Intervention quit rates
were derived from literature. Medical savings result from
the higher quit rate associated with the interventions.
Non-medical savings accrue to the employer because of
reduction in smoking breaks as well as illness days. The
ROI is calculated as the net (medical and non-medical)
savings over program costs. RESULTS: In a commercially
insured population of 980,292 members, the combined
interventions generate positive net savings of $0.02 per
member per month (PMPM) at the end of ﬁrst year. They
generate gross savings of $0.17 PMPM, only 33% of
which are from medical savings. First year ROI is esti-
mated to be 16% and predicted to increase signiﬁcantly
over the next 20 years. Eliminating non-medical savings
from the analysis will result in a negative ROI in the ﬁrst
year but will not affect the positive net savings past year
5. CONCLUSIONS: MediSave Smoking Cessation is an
effective tool in making the business case for tobacco
control programs. In our study, the combined impact of
pharmaceuticals and physician advice is cost-beneﬁcial.
The interventions produce substantial non-medical
savings in the short term and generate signiﬁcant medical
savings in the long term.
CARDIOVASCULAR DISEASES/DISORDERS—
Quality of Life/Preference Based Outcomes
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OBJECTIVE: Two relatively common myths regarding
the impact of obesity on quality of life are: 1) women are
